PROGEN — Prostatype Genomics AB Share Price
0.000.00%
Last trade - 00:00- SEK80.26m
- SEK78.47m
- SEK1.36m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.04 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 78.45 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -287.02% | ||
| Return on Equity | -256.38% | ||
| Operating Margin | -3727.57% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 0.07 | 0.68 | 0.01 | 0.68 | 1.36 | 13 | 56 | 52.98% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Prostatype Genomics AB is a Sweden-based company developing gene tests. The Company's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- March 12th, 2007
- Public Since
- November 3rd, 2020
- No. of Employees
- 7
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 5,944,867,116
- Address
- Industrivagen 19, SOLNA, 169 73
- Web
- https://www.prostatypegenomics.com/
- Phone
- +46 8208700
- Auditors
- Grant Thornton Sweden AB
Upcoming Events for PROGEN
Similar to PROGEN
Ambea AB (publ)
OMX Nordic Exchange Stockholm
Attendo AB (publ)
OMX Nordic Exchange Stockholm
Bonzun AB (publ )
OMX Nordic Exchange Stockholm
Humana AB
OMX Nordic Exchange Stockholm
Medhelp Care AB (publ)
OMX Nordic Exchange Stockholm
FAQ
What is the Prostatype Genomics AB share price?
As of Today at 22:46 UTC, shares in Prostatype Genomics AB are trading at SEK0.01. This share price information is delayed by 15 minutes.
How has the Prostatype Genomics AB share price performed this year?
Shares in Prostatype Genomics AB last closed at SEK0.01 and the price had moved by -92.79% over the past 365 days. In terms of relative price strength the Prostatype Genomics AB share price has underperformed the FTSE Global All Cap Index by -93.78% over the past year.
What are the analyst and broker recommendations for Prostatype Genomics AB?
There is no consensus recommendation for this security.
Find out moreWhat is the Prostatype Genomics AB dividend yield?
Prostatype Genomics AB does not currently pay a dividend.
Does Prostatype Genomics AB pay a dividend?
Prostatype Genomics AB does not currently pay a dividend.
When does Prostatype Genomics AB next pay dividends?
Prostatype Genomics AB does not currently pay a dividend.
How do I buy Prostatype Genomics AB shares?
To buy shares in Prostatype Genomics AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Prostatype Genomics AB?
As of the previous close price of SEK0.01, shares in Prostatype Genomics AB had a market capitalisation of SEK80.26m.
Where are Prostatype Genomics AB shares listed?
Here are the trading details for Prostatype Genomics AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: PROGEN
What kind of share is Prostatype Genomics AB?
Based on an overall assessment of its quality, value and momentum Prostatype Genomics AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Prostatype Genomics AB share price forecast for 2024?
The analyst consensus target price for shares in Prostatype Genomics AB is SEK0.58. That is 4196.3% above the last closing price of SEK0.01.
Analysts covering Prostatype Genomics AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.10 for the next financial year.
Find out moreWhat is the trend in the Prostatype Genomics AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Prostatype Genomics AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -78.19%.
As of the last closing price of SEK0.01, shares in Prostatype Genomics AB were trading -68.57% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Prostatype Genomics AB PE Ratio?
The Prostatype Genomics AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Prostatype Genomics AB?
We do not have data on Prostatype Genomics AB's directors